Puma Biotechnology (NASDAQ:PBYI – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday. Separately, HC Wainwright decreased their target price on shares of Puma Biotechnology from $8.00 to $7.00 and set a “buy” rating for the company in a research report […] Read this story
